Standing on the top of the stars, the glory is extraordinary.
It has been ten years since the summit forum of Chinese listed companies hosted by the daily economic news. With the annual reputation list selection of the summit forum, it has gone through 11 spring and autumn. On December 24, the results of the 11th public praise list of Chinese listed companies were officially announced.
As the most dynamic and innovative hope of China’s economy, more than 100 listed companies are the cream of more than 4000 A share listed companies. For more than 10 years, the daily economic news, like many selected excellent listed companies, has resonated with the same frequency with China’s high-quality development, and has continuously helped China’s capital market to stabilize and go far.
It is worth noting that the best listed company CEO award in this selection can be described as shining stars. Sichuan Kelun Pharmaceutical Co.Ltd(002422) general manager Liu Sichuan was on the list. Rooted in Sichuan Kelun Pharmaceutical Co.Ltd(002422) of innovative R & D, the company has been innovating in recent years. From the infusion field to the “three engine drive”, it is ushering in a critical moment when new products are listed one after another. The company also won the honor of “the most growing listed company” in the biomedical industry.
innovation opens a space for sustainable growth
After more than three months of screening and selection, the 11th China listed company reputation list adds the most deserved honor to more than 100 listed companies that seriously do their main business and stick to their value.
This is the 11 years since the daily economic news launched the selection of the public praise list of listed companies. As one of the most influential activities in the industry, the gold content of the selection has been noticed by the outside world through the continuous search and selection of companies with capital market value growth.
With the continuous deepening in the field of pharmaceutical innovation and R & D, and bravely challenge the social responsibility of enterprise development. Sichuan Kelun Pharmaceutical Co.Ltd(002422) won the honor of the most growing listed company and the most socially responsible listed company in the biomedical industry in this public praise list. As the post-80s Young Marshal in charge of collen, Sichuan Kelun Pharmaceutical Co.Ltd(002422) general manager Liu Sichuan also ranked among the best CEOs.
This honor is a powerful recognition of Sichuan Kelun Pharmaceutical Co.Ltd(002422) and praise for Sichuan Kelun Pharmaceutical Co.Ltd(002422) ‘s efforts and struggle in the competitive and incentive pharmaceutical industry.
For Yu Kelun, innovation is not a slogan, but a carefully analyzed practice. The logic behind it is to realize the sustainable development of enterprise innovation through R & D technology and productivity reform, so as to jump out of the simple and repeated labor cycle.
As early as 2012, Sichuan Kelun Pharmaceutical Co.Ltd(002422) announced the full start of innovation and transformation.
After 10 years of layout, Sichuan Kelun Pharmaceutical Co.Ltd(002422) has invested more than 7 billion yuan in R & D and innovation. Kelun innovative drug research aims at solving the unmet clinical needs, combines the future competitive situation, starts from the end, pursues the differentiation advantage and production cost advantage with clinical value from project approval to production and marketing, and is committed to developing products with market competitiveness of me better and best in class.
In recent years, Sichuan Kelun Pharmaceutical Co.Ltd(002422) has continued to increase its investment in innovative R & D. According to the data, from 2015 to 2019, the R & D investment of the company was 498 million yuan, 613 million yuan, 846 million yuan, 1114 million yuan and 1351 million yuan respectively. In 2020, Sichuan Kelun Pharmaceutical Co.Ltd(002422) R & D investment will reach a new high. According to the 2020 annual report, the company invested 1.516 billion yuan in R & D, a year-on-year increase of 12.24%.
In the first half of this year, Sichuan Kelun Pharmaceutical Co.Ltd(002422) R & D investment was 814 million yuan, a year-on-year increase of 5.83%, and the proportion of R & D investment in sales revenue further increased to 9.88%, ranking the first echelon among China’s large-scale commercialized pharmaceutical enterprises.
By the end of June 2021, Kelun innovation pipeline had 85 projects under research (38 innovative small molecules and 47 biotechnological drugs), focusing on tumors. At the same time, it has arranged the fields of liver diseases, cardiovascular diseases, anesthesia and analgesia, autoimmunity and other diseases, forming the advantages of disease cluster and product iteration. Among them, there are 14 clinical projects in the innovative clinical research stage, 13 projects in the preclinical development stage and more than 50 projects in the drug discovery stage.
In the pharmaceutical industry, innovative pharmaceutical enterprises such as Kelun are often easier to stand out in the market competition. By innovating industry resources and creating jobs systematically and rationally, they create industry competition barriers, and the market often gives more reasonable pricing.
This also means that when making investment decisions, investors should hope to examine the investment logic and value from a long-term perspective and think about the industry environment, market space, sustainable growth, internal governance, valuation and other models of the company, so as to share the long-term dividends brought by enterprise growth.
brave social responsibility
The enterprise tenet of Sichuan Kelun Pharmaceutical Co.Ltd(002422) is “seeking truth in science and seeking goodness in ethics”.
Since its establishment, Sichuan Kelun Pharmaceutical Co.Ltd(002422) has always kept in mind the social responsibility of “corporate citizens”, continued to increase investment, actively participated in various public welfare undertakings, and strive to benefit the people’s livelihood and give back to the society.
With the sudden outbreak of pneumonia in COVID-19, Sichuan Kelun Pharmaceutical Co.Ltd(002422) employees went back to the forefront of fighting New Coronavirus with extraordinary courage and enthusiasm, competing against the clock to deliver supplies to the medical team. Donated tens of millions of yuan worth of protective clothing, masks and other scarce medical materials to support epidemic prevention and control throughout the country, opened a green channel for material transportation of medical teams assisting Hubei, and helped 66 medical teams transport 84 batches of scarce protective materials.
In July this year, Henan suffered sustained Extreme Heavy Rainfall and regional severe floods in many places. After the disaster, Henan Kelun, a wholly-owned subsidiary of Sichuan Kelun Pharmaceutical Co.Ltd(002422) , immediately established an emergency command group to organize all employees to fight the flood.
On July 23, with a high sense of social responsibility and mission, Henan Kelun donated 5 million yuan in cash through Henan Charity Federation for emergency rescue in heavy rainfall disaster areas in Henan. The donated funds are specially used to purchase emergency relief materials and support local post disaster killing and epidemic prevention and health undertakings.
Wenchuan earthquake, Lushan earthquake, covid-19 epidemic, Henan flood and other major events, Sichuan Kelun Pharmaceutical Co.Ltd(002422) often lend a helping hand at the first time, highlighting the mission and responsibility of an enterprise.
In addition, Sichuan Kelun Pharmaceutical Co.Ltd(002422) has contributed more than 200 million yuan to social public welfare undertakings, glorious undertakings and charities over the years in the form of industrial assistance, medical assistance, educational assistance and ecological assistance.
Continuous development and responsibility. Adhere to the high unity of economic and social benefits, achieve transcendental development and self-change in the overall pattern of medicine, and always “shoulder morality with iron shoulder” to help build a healthy China.
This time Sichuan Kelun Pharmaceutical Co.Ltd(002422) won the “most socially responsible listed company”, which is a high affirmation of Sichuan Kelun Pharmaceutical Co.Ltd(002422) in fulfilling social responsibilities and realizing social benefits. In the future, collen will also continue to practice the mission and vision of enterprise development, seek high-quality development of medicine, take transmitting positive value as its own responsibility, and create a new future for the development of pharmaceutical enterprises.
(Daily Economic News)
